Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease
Published on 23. December 2009
Book
Hardback
388 pages
978-0-89603-727-4 (ISBN)
Description
This book provides a definitive basis of knowledge of the use of glycoprotein IIb/IIIa inhibitors for the treatment of cardiac diseases and for the prevention of ischemic complications after percutaneous coronary intervention. The first section concentrates on the basic pathophysiology underlying the theoretical usefulness and development of this class of agents. It covers the role of thrombosis and platelet activity as well as cell surface adhesion molecules. The second section concentrates on the GP IIb/IIIa blockade following percutaneous coronary revascularization. Three agents are reviewed for this indication (abciximab Integrilin and tirofiban) with a focus on the data derived from the major Phase III trials. This section concludes with a key summary integrating the results of the major trials of GP IIb/IIIa during coronary intervention comparing and contrasting the different agents and providing practical guidelines for clinical use. The third section focuses on the emerging indication of GP IIb/IIIa blockade during the acute coronary ischemic syndromes: unstable angina and acute myocardial infarction discussing the major Phase II trials and ongoing studies in the filed.
The fourth and final section provides a vision of the future development and application of these agents for the treatment of vascular disease including the new frontier of chronic antiplatelet therapy with oral GP IIb/IIIa agents and the potential role of these agents in non-coronary (peripheral and cerebral) vascular disease.
The fourth and final section provides a vision of the future development and application of these agents for the treatment of vascular disease including the new frontier of chronic antiplatelet therapy with oral GP IIb/IIIa agents and the potential role of these agents in non-coronary (peripheral and cerebral) vascular disease.
Reviews / Votes
Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease claims to be a comprehensive, definitive, and detailed overview of the preclinical and clinical development of the class of glycoprotein IIb/IIIa receptor antagonists. It is. For the most part, this book achieves its four goals: elucidating the theoretical basis for platelet inhibition in treatment of coronary syndromes, presenting and synthesizing the evidence for the efficacy of glycoprotein IIb/IIIa blockade in coronary interventions and acute coronary syndromes, providing guidelines for the use of this class of agents, and anticipating future applications...The authors are authorities in their respective areas...Presentations are generally clear and well organized, and chapters are well illustrated with diagrams, graphs, and charts as the material warrants. as a single resource covering virtually the entire spectrum of information related to GPIs, it will be extremely valuable to cardiology interventionists, health care practitioners concerned with management of coronary ischemic syndromes, and formulary committees charged with ensuring cost effective use of these expensive agents. - The Annals of PharmacotherapyMore details
Series
Language
English
Place of publication
Totowa, NJ
United States
Target group
College/higher education
Professional and scholarly
Product notice
Laminated cover
Dimensions
Height: 178 mm
Width: 254 mm
Thickness: 22 mm
Weight
888 gr
ISBN-13
978-0-89603-727-4 (9780896037274)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
New editions
A. Michael Lincoff
Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease
Book
03/2003
2nd Edition
Humana Press Inc.
€213.99
Shipment within 15-20 days
Content
Part I. Basic Principles. Thrombosis in Acute Coronary Syndromes and Coronary Interventions Thaddeus R. Tolleson and Robert A. Harrington. Mechanisms of Platelet Adhesion Edward F. Plow. GPIIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis Debbie A. Law and David R. Phillips. GPIIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Select Agents. Part III. GP IIb/IIIa Blockade During Coronary Intervention. Abciximab in Coronary Intervention: EPIC EPILOG EPISTENT Trials A. Michael Lincoff. Integrilin in Coronary Intervention: The IMPACT Trials Conor O'Shea and James E. Tcheng. Tirofiban in Coronary Intervention: The RESTORE Trial Mohamed Y. Salame Spencer B. King III and Nicolas A. Chronos. Use of Abciximab in Therapy Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot and the CAPTURE Study Marcel J. B. M. van den Brand and Maarten L. Simoons. Overview of the GP IIb/IIIa Interventional Trials A. Michael Lincoff and Eric J. Topol. Part III. GP IIb/IIIa Blockade for Acute Ischemic Syndromes. Unstable Angina: PURSUIT PARAGON PRISM and PRISM Plus David J. Molitemo and Harvey D. White. The Use of Glycoprotein IIb/IIIa in Acute Myocardial Infarction Adam B. Greenbaum Robert A. Harrington and E. Magnus Ohman. Part IV. Practical Issues and Future Applications. Economics of Glycoprotein IIb/IIIa Inhibition Daniel B. Mark. Monitoring Platelet Aggregation Neal S. Kleiman Wojciech Mazur and Nikki Graziadei. Oral Platelet Glycoprotein IIb/IIIa Blockade Dean J. Kereiakes and Christopher P. Cannon. Cerebrovascular Aspects of Glycoprotein IIb/IIIa Inhibitors Cathy A. Sila. The Future of Glycoprotein IIb/IIIa Inhibitors Robert M. Califf and David F. Kong.